Benzinga · Aug 21, 2026
Gold Moves Higher; US Composite PMI Surges In August
Dow gains 400 points, Materials sector up 2.3%, Werewolf Therapeutics up 113%, S&P PMI rises to strongest level since April 2022.
NASDAQ · HOWL
Healthcare · Biotechnology
$0.98
Down-$0.00 (-0.03%)
Updated Sep 16, 2026, 5:46 PM
SID Score
5.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
HOWL closed at $0.98 after 20 trading sessions, up 139.49% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $0.9506 | $0.9817 | $0.923 | $0.98 | 1.21M |
| Sep 14, 2026 | $0.97 | $0.9948 | $0.93 | $0.9579 | 969.89K |
| Sep 11, 2026 | $0.97 | $1.02 | $0.96 | $0.982 | 549.2K |
| Sep 10, 2026 | $0.96 | $0.9885 | $0.9501 | $0.9885 | 901.79K |
| Sep 9, 2026 | $0.9749 | $0.9895 | $0.9501 | $0.965 | 867.59K |
| Sep 8, 2026 | $0.96 | $0.99 | $0.943 | $0.98 | 671.09K |
| Sep 4, 2026 | $0.94 | $0.9671 | $0.9301 | $0.9663 | 489.8K |
| Sep 3, 2026 | $0.97 | $1.02 | $0.9333 | $0.9438 | 1.33M |
| Sep 2, 2026 | $0.9429 | $0.9983 | $0.9401 | $0.9983 | 1.31M |
| Sep 1, 2026 | $0.9174 | $0.9675 | $0.912 | $0.9575 | 982.57K |
| Aug 31, 2026 | $0.935 | $0.9489 | $0.90 | $0.941 | 1.27M |
| Aug 28, 2026 | $0.9747 | $1.03 | $0.9273 | $0.9433 | 2.33M |
| Aug 27, 2026 | $0.99 | $0.9981 | $0.9144 | $0.9708 | 2.22M |
| Aug 26, 2026 | $0.90 | $1.05 | $0.8979 | $0.9888 | 11.62M |
| Aug 25, 2026 | $0.8656 | $0.9344 | $0.84 | $0.89 | 6.43M |
| Aug 24, 2026 | $0.85 | $0.90 | $0.811 | $0.8833 | 12.04M |
| Aug 21, 2026 | $0.98 | $1.05 | $0.86 | $0.8735 | 296.73M |
| Aug 20, 2026 | $0.4221 | $0.44 | $0.4033 | $0.4312 | 66.02M |
| Aug 19, 2026 | $0.4092 | $0.42 | $0.4033 | $0.4093 | 155.58K |
| Aug 18, 2026 | $0.3997 | $0.4161 | $0.3997 | $0.4092 | 87.22K |
The latest Smart Investors Daily articles mentioning HOWL.
HOWL research
Company profile and research snapshot.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Dec 19, 2025 | HC Wainwright & Co. | Buy | — |
| Nov 18, 2025 | B of A Securities | Buy | — |
| Aug 25, 2025 | B of A Securities | Buy | — |
| Aug 21, 2025 | JMP Securities | Market Outperform | — |
| May 9, 2025 | Wedbush | Outperform | — |
No generated briefing is available yet.
Benzinga · Aug 21, 2026
Dow gains 400 points, Materials sector up 2.3%, Werewolf Therapeutics up 113%, S&P PMI rises to strongest level since April 2022.
Benzinga · Aug 21, 2026
Werewolf Therapeutics and Ambros Therapeutics merge in an all-stock deal with $150M in financing to advance Phase 3 CRPS-1 candidate.
Benzinga · Aug 21, 2026
Werewolf Therapeutics surged after announcing a $500 million merger with Ambros Therapeutics, putting focus on Israel Englander's holding.
Benzinga · Aug 21, 2026
Werewolf Therapeutics shares surge 89.94% after hours as $33 million deal with EMD Serono brings fresh non-dilutive cash.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning HOWL.